Showing 6041-6050 of 9414 results for "".
- Skinbetter scienceTM Debuts with Launch of New Anti-aging Productshttps://practicaldermatology.com/news/skinbetter-sciencetm-debuts-with-launch-of-new-anti-aging-products/2458478/Introducing skinbetter scienceTM ... the brainchild of Jonah Shacknai and several former members of the Medicis leadership team among others. The new line will debut in physician offices nationwide in August 2016. The
- MRF to UPSTF: Reconsider Supporting Annual Skin Cancer Checkshttps://practicaldermatology.com/news/mrf-to-upstf-reconsider-support-for-annual-skin-cancer-checks/2458479/The Melanoma Research Foundation (MRF) is urging the U.S. Preventive Services Task Force’s (USPSTF) to reconsider their recent announcement stating that insufficient data exists to support a recommendation for annual skin canc
- ASDS Disagrees with New Skin Cancer Screening Recommendationhttps://practicaldermatology.com/news/asds-disagrees-with-new-skin-cancer-screening-recommendation/2458483/The US Preventive Service Task Force (USPSTF) has declined to take a stance on the value of preventive skin cancer screenings for the second time in seven years, and The American Society for Dermatologic Surgery ASDS is responding with disappointment. The USPSTF says there is insufficient
- Almirall, Sun Pharma Enter into a License Agreement for Psoriasis Drug Tildrakizumab in Europehttps://practicaldermatology.com/news/almirall-sun-pharma-enter-into-a-license-agreement-for-psoriasis-drug-tildrakizumab-in-europe/2458485/Sun Pharmaceutical Industries Ltd and Almirall will work together to develop and commercialize tildrakizumab for psoriasis in Europe. Tildrakizumab is an investigational IL-23p19 inhibitor currently being e
- Mission Pharmacal Expands Dermatology Commitment with the Acquisition of GlyDermhttps://practicaldermatology.com/news/mission-pharmacal-expands-dermatology-commitment-with-the-acquisition-of-glyderm/2458487/Espada Dermatology, Inc, a wholly-owned subsidiary of Mission Pharmacal Company, purchased the GlyDerm line of skin care products from Lautus Pharmaceuticals, LLC. Prior to this acquisition, Mission offered prescription dermatological products solely through Mission Dermatology
- FDA Cracks Down on Mercury in Anti-Aging Productshttps://practicaldermatology.com/news/fda-cracks-down-on-mercury-in-anti-aging-products/2458488/The U.S. Food and Drug Administration is re-issuing a warning about the dangers of mercury in skin creams, beauty and antiseptic soaps, and lotions. In the past few years, the FDA and state health officials
- Summer 2016's Must-Have Accessory: La Roche-Posay's New UV Patch Available Nowhttps://practicaldermatology.com/news/summer-2016s-must-have-accessory-la-roche-posays-new-uv-patch-available-now/2458491/La Roche-Posay’s new UV patch monitor and companion app are here. My UV Patch measures UV exposure in real time. The water- and sweat-resistant patch can be used for up to three days during all outdoor activities. It is approximately one square inch and 50 micrometers thick &n
- Galderma and Chugai Announce Global License Agreement for Nemolizumab, Novel Biologic for Skin Diseaseshttps://practicaldermatology.com/news/galderma-and-chugai-announce-global-license-agreement-for-nemolizumab-novel-biologic-for-skin-diseases/2458496/Chugai Pharmaceutical Co., Ltd. and Galderma Pharma S.A. have entered into a global license agreement for nemolizumab (CIM331), the anti-IL-31 receptor A humanized monoclonal antibody created by Chugai, which is currently under development for atopic dermatitis and pruritus in hemodialysis patien
- Indoor Tanning Rates Among Minors in NJ Stays Same Despite 2013 Banhttps://practicaldermatology.com/news/indoor-tanning-rates-among-minors-in-nj-stays-same-despite-2013-ban/2458494/Indoor tanning rates among children under age 17 in New Jersey didn’t budge after a ban enacted in 2013, and rates increased among male high school students in the Garden State from 2012 to 2014, according to a study in the Journal
- FDA Advisory Arm Recommends Brodalumab For Moderate-To-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-advisory-arm-recommends-brodalumab-for-moderate-to-severe-plaque-psoriasis/2458497/A US. Food and Drug Administration (FDA) advisory panel voted to greenlight Valeant’s IL-17 blocker brodalumab for the treatment of moderate-to-severe plaque psoriasis in adults. The committee voted 18 to 0 in favor of brodalumab injection, 210